UPDATE 1-Discovery Labs lung drug disappoints in mid-stage trial

* Drug did not significantly cut artificial breathing time

* Says drug was safe and well tolerated

* Drug is to treat pediatric respiratory failure

June 9 (BestGrowthStock) – Discovery Laboratories Inc (DSCO.O: )
said its lung drug did not show statistically significant
reduction in the time of artificial breathing in children
suffering from acute respiratory failure in a mid-stage study.

The study enrolled 165 children with acute respiratory
failure, who received either the drug Surfaxin or a dummy drug.

The objective of the study was to evaluate the safety and
tolerability of the drug and to assess whether Surfaxin
treatment could decrease the duration of mechanical
ventilation, the company said.

The company said Surfaxin treatment reduced time on
mechanical ventilation by about 10 percent, which was not
statistically significant, compared to the group receiving the
dummy drug.

However, the drug was generally safe and well tolerated and
the company expects further assessment of safety and
tolerability of the drug to be completed in the third quarter.

Shares of the company closed at $0.40 Tuesday on Nasdaq.

Stock Market Today

(Reporting by Krishnakali Sengupta in Bangalore;Editing by
Prem Udayabhanu)

UPDATE 1-Discovery Labs lung drug disappoints in mid-stage trial